Good news, Ebola vaccine manufactured with 100% success rate

More than 7,500 people who came into contact with Ebola victims were protected from the deadly disease by a new vaccine
A vaccine for the Ebola virus has been created which is 100 per cent effective, the World Health Organisation said today.
Results from a trial in Guinea show that VSV-EBOV protected all 7,500 people who had been in close contact with Ebola patients after just a single dose.
Although trials are continuing, the World Health Organisation said the results were ‘extremely promising’ while the findings were described as ‘remarkable’ by the Wellcome Trust, which partly funded the research.
The Guinea vaccination trial began in affected communities on 23 March 2015 and targeted family members, neighbours and co-workers of Ebola victims.

While the vaccine up to now shows 100 per cent efficacy in individuals, the researchers say more conclusive evidence is needed on its capacity to protect populations. A new trial will now include 13 to 17-year-old and possibly 6 to 12-year-old children on the basis of new evidence of the vaccine’s safety.
“This is an extremely promising development,” said Dr Margaret Chan, Director-General of the World Health Organization.
“The credit goes to the Guinean Government, the people living in the communities and our partners in this project. An effective vaccine will be another very important tool for both current and future Ebola outbreaks.”

The trial is being run by the Guinean authorities, WHO, Médecins sans Frontières (MSF) and the Norwegian Institute of Public Health, with support from a broad partnership of international and national organizations.
“This is Guinea’s gift to West Africa and the world,” said Dr. Sakoba Keita, Guinea’s national coordinator for the Ebola response.
“The thousands of volunteers from Conakry and other areas of Lower Guinea, but also the many Guinean doctors, data managers and community mobilisers have contributed to finding a line of defence against a terrible disease.”
More than year on from the first confirmed case recorded on 23 March 2014, at least 11,178 people have been reported as having died from the disease in six countries; Liberia, Guinea, Sierra Leone, Nigeria, the US and Mali.The total number of reported cases is more than 27,275.
It is thought the outbreak was sparked by a two year old boy playing with a fruit bat. Experts at Public Health England (PHE) studied the genetic mutations of the virus and traced original strain back to a small village of Meliandou in Guinea, West Africa.
The toddler died of unidentified causes on December 3 2013 followed a week later by his mother, then three-year-old sister and grandmother. Mourners at the grandmother's funeral then took the virus to other villages.

Jeremy Farrar, Director of the Wellcome Trust, said: “This is a remarkable result which shows the power of equitable international partnerships and flexibility,” said Jeremy Farrar, Director of the Wellcome Trust, one of the funders of the trial. “
"This partnership also shows that such critical work is possible in the midst of a terrible epidemic. It should change how the world responds to such emerging infectious disease threats.
“We, and all our partners, remain fully committed to giving the world a safe and effective vaccine. ”

The findings were published in The Lancet.